OR4A17P: A Potential Drug Target and Biomarker for Various Diseases
OR4A17P: A Potential Drug Target and Biomarker for Various Diseases
OR4A17P (OR4A22P), a protein located in the O-type Gelatin family, is a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. OR4A17P has unique features that make it an attractive target for drug development due to its intercellular localization, stability, and role in various cellular processes.
OR4A17P is a 22kDa protein that is expressed in various tissues, including brain, heart, skeletal muscles, and placenta. It is primarily localized to the peri-nucleosomal region, which is a region between the nuclear membrane and the nuclear chromatin. OR4A17P is known to play a role in the regulation of gene expression and has been implicated in various cellular processes, including cell adhesion, migration, and invasion.
One of the key functions of OR4A17P is its role in the regulation of microRNA (miRNA) levels. OR4A17P has been shown to interact with miRNA-21, a well-known regulator of gene expression, and can either enhance or decrease the levels of miRNA -21 in different cell types. This interaction between OR4A17P and miRNA-21 suggests that OR4A17P may be a useful biomarker for tracking the effects of drugs that target miRNA-21.
OR4A17P is also known to be involved in the regulation of the protein kinase B (PKB) signaling pathway. The PKB pathway is a well-established signaling pathway that regulates various cellular processes, including cell growth, differentiation, and survival. OR4A17P has been shown to play a role in the regulation of PKB signaling by interacting with the protein p110, which is a key component of the PKB complex. This interaction between OR4A17P and p110 suggests that OR4A17P may be a potential drug target for inhibiting PKB signaling.
In addition to its role in miRNA and PKB signaling, OR4A17P has also been implicated in the regulation of various cellular processes that are relevant to cancer progression. For example, OR4A17P has been shown to be involved in the regulation of cell cycle progression, which is a critical step in the development of cancer. OR4A17P has also been shown to play a role in the regulation of apoptosis, which is a critical mechanism for cell death that is often disrupted in cancer cells.
OR4A17P's role in the regulation of cell cycle progression and apoptosis makes it an attractive target for drugs that aim to inhibit the development and progression of cancer. Additionally, OR4A17P's localization to the peri-nucleosomal region suggests that it may be a good candidate for small molecule inhibitors that can be specifically targeted to this region of the cell.
OR4A17P is also a potential biomarker for neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. These disorders are characterized by the progressive loss of brain cells and can result in a range of symptoms, including cognitive impairment, tremors, and decline in quality of life . OR4A17P has been shown to play a role in the regulation of neurodegenerative disorder progression by interacting with the protein neurotrophin (NTPR), which is a critical signaling molecule in the brain.
OR4A17P's role in the regulation of NTPR signaling suggests that it may be a potential drug target for neurodegenerative disorders. Additionally, the fact that OR4A17P is expressed in various tissues, including brain, heart, and skeletal muscles, suggests that it may be a useful biomarker for tracking the effects of drugs that target this protein in different parts of the body.
OR4A17P may also be a potential drug target for autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. These disorders are characterized by the immune system attacking the body's own tissues, leading to inflammation and various symptoms. OR4A17P has been shown to play a role in the regulation of immune cell function by interacting with the protein PD-L1, which is a critical
Protein Name: Olfactory Receptor Family 4 Subfamily A Member 17 Pseudogene
The "OR4A17P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OR4A17P comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
OR4A21P | OR4A47 | OR4A5 | OR4B1 | OR4C11 | OR4C12 | OR4C13 | OR4C15 | OR4C16 | OR4C1P | OR4C3 | OR4C45 | OR4C46 | OR4C5 | OR4C50P | OR4C6 | OR4D1 | OR4D10 | OR4D11 | OR4D2 | OR4D5 | OR4D6 | OR4D9 | OR4E2 | OR4F13P | OR4F15 | OR4F16 | OR4F17 | OR4F21 | OR4F29 | OR4F3 | OR4F4 | OR4F5 | OR4F6 | OR4G3P | OR4K1 | OR4K13 | OR4K14 | OR4K15 | OR4K17 | OR4K2 | OR4K5 | OR4K6P | OR4K7P | OR4L1 | OR4M1 | OR4M2 | OR4M2-OT1 | OR4N2 | OR4N3P | OR4N4 | OR4N5 | OR4P4 | OR4Q3 | OR4S1 | OR4S2 | OR4T1P | OR4V1P | OR4X1 | OR4X2 | OR51A1P | OR51A2 | OR51A3P | OR51A4 | OR51A6P | OR51A7 | OR51B2 | OR51B4 | OR51B5 | OR51B6 | OR51C1P | OR51D1 | OR51E1 | OR51E2 | OR51F1 | OR51F2 | OR51G1 | OR51G2 | OR51H1 | OR51I1 | OR51I2 | OR51J1 | OR51L1 | OR51M1 | OR51Q1 | OR51S1 | OR51T1 | OR51V1 | OR52A1 | OR52A4P | OR52A5 | OR52B2 | OR52B4 | OR52B6 | OR52D1 | OR52E1 | OR52E2 | OR52E4 | OR52E5 | OR52E6
